US › Healthcare

Seres Therapeutics Inc (MCRB)

US · Healthcare · Biotechnology

$5.25+4.37%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$358,000
Net profit
$-19.9M
Profit YoY
-160.9%
EPS
$-2.08
EPS estimate
$-1.88
Net margin
-5,562.3%

EPS came in at -2.08 against a street estimate of -1.88 — a miss of 10.6%.

Key statistics

Market cap
$46.8M
Forward P/E
10.3
P/B
1.77
Book value
$2.76
EPS (TTM)
$-5.20
52-week high
$29.98
52-week low
$4.59
50-day MA
$6.47
200-day MA
$11.25
Beta
0.10

Analyst view

Analysts rate Seres Therapeutics Inc a buy (2 buy, 2 hold, 1 sell out of 5) with an average price target of $17.00.

Shareholding

Insiders
11.78%
Institutions
23.98%

Largest institutional holders

FundStake
Flagship Ventures Management, Inc.11.94%
Vanguard Capital Management, LLC3.04%
Marshall Wace Asset Management Ltd1.44%
Vontobel Holding Ltd.1.43%
Susquehanna International Group, LLP1.09%
BlackRock Inc1.05%
Geode Capital Management, LLC0.77%
American Century Companies Inc0.64%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Seres Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.